An observational study in Frailty and Septic Shock, sponsored by Centre Hospitalier de Lens. Recruiting at 5 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Centre Hospitalier de Lens · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Frailty with a site in France — 23 open to participants now, 25 under way, none of them phase 3. Frailty · France.
Among the 59 studies in Frailty with a site in France, this one is the 16th largest by planned enrollment of the 32 observational ones that give a count, is one of 6 that started in 2023, is one of 32 observational ones, reaches primary completion later than 12 of the 24 other live ones, and was the 36th registered.
1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.
Browse Frailty studies →23 of the 59 studies in Frailty with a site in France are open now. Recruiting first, the newest first:
Fondation Hôpital Saint-Joseph · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 70+
University Hospital, Toulouse · Sites in France
Ages 70+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 65+
University Hospital, Bordeaux · Sites in France
Ages 75+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2023.
This study's planned enrollment of 200 is below the median of 225 across 495 observational studies indexed under Frailty.
Median enrollment 106 across the 27 interventional studies, 200 across the 32 observational. Of the 29 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 59 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier de Lens is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Centre Hospitalier de Lens has 1 study filed under Frailty — fewer than ten, so there is no comparison to draw.
7 of the studies in Frailty with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06247189University Hospital, ToulouseICOPE Program Feasibility in the Management of Myeloma Patients | 2026-12-03 |
| NCT06513130University Hospital, Strasbourg, FranceGeriatric Assessment at Discharge From the Intensive Care Unit in Patients Aged 75 Years and Older: a Feasibility Study | 2027-01-02 |
| NCT06887075University Hospital, BordeauxSystemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation | 2027-02-15 |
| NCT07348081Fondation Hôpital Saint-JosephReal World Evidence to Assess the Value of a Digital Care Coordination and Monitoring Program for Supporting Caregivers of Adults Discharged From the Emergency Department. | 2027-03-12 |
| NCT07379099MSPU de Pins-JustaretImplementation of the Personalized Care Plan (PCP) Proposed at the End of Step 2 of the ICOPE Program | 2027-06-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 59 studies in Frailty with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to demonstrate that "frail" patients, defined as having a CFS score greater than or equal to 5, and "severely" frail patients, defined as having a CFS score between [6-7] as defined by Bagshaw et al (14), constitute an independent risk factor (RF) for mortality.
In the same way, as an exploratory study, we will try to find out whether clinical frailty constitutes a risk factor for extending the length of hospital stay, the risk of short/medium-term readmission, as has already been demonstrated for patients admitted to intensive care from all causes (15), or for impaired quality of life.
The objective is to have a better understanding of the implications and outcomes associated with pre-hospital frailty in young critically ill patients.
This analysis will also help to clarify prognoses and contribute to better decision-making on the intensity and proportionality of care, as well as providing better information and helping to manage the expectations of patients and their families in terms of survival prognosis and subsequent quality of life.
Recent studies show the impact of frailty in a middle-aged or even young population of patients admitted to critical care in terms of mortality (13), and the persistent risk of impairment of physical and mental capacities after resuscitation (14). To date, few studies have looked at clinical frailty as a risk factor for mortality in a middle-aged or young population, more specifically those suffering from septic shock, which is already known to be a major factor in morbidity and mortality (15,16), with repercussions on long-term quality of life.
The aim of the study is to demonstrate that "frail" patients, defined as having a CFS score greater than or equal to 5, and "severely" frail patients, defined as having a CFS score between [6-7] as defined by Bagshaw et al (14), constitute an independent risk factor (RF) for mortality.
In the same way, as an exploratory study, we will try to find out whether clinical frailty constitutes a risk factor for extending the length of hospital stay, the risk of short/medium-term readmission, as has already been demonstrated for patients admitted to intensive care from all causes (15), or for impaired quality of life.
The objective is to have a better understanding of the implications and outcomes associated with pre-hospital frailty in young critically ill patients.
This analysis will also help to clarify prognoses and contribute to better decision-making on the intensity and proportionality of care, as well as providing better information and helping to manage the expectations of patients and their families in terms of survival prognosis and subsequent quality of life.
All patients admitted to intensive care will be studied for this study. Patients meeting the inclusion criteria and with no non-inclusion criteria will be included in the study after obtaining the patient's or relative's, if applicable, non-objection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To show that the frailty score on admission is a risk factor for mortality at D28, independent of known risk factors, in young patients admitted to intensive care (ICU) for sepsis or septic shock.
The odds ratio of frail patients to non-frail patients for the risk of all-cause death at D28
Time frame: 28 days after inclusion
To study the association, independently of known risk factors, between the frailty score on admission and mortality at day 90.
Time from admission to death or last news, censored at D90
Time frame: 90 days after inclusion
To study the association, independently of known risk factors, between the frailty score on admission and length of hospital stay
The time between admission to IS and live discharge from hospital, death is considered a concurrent risk, the data are censored at 90 days
Time frame: 90 days after inclusion
To study the association, independently of known risk factors, between the frailty score on admission and the number of days with recourse to invasive therapies
Number of days with mechanical ventilation, with amines, with recourse to extra-renal purification (EER) during the IS stay.
Time frame: 90 days after inclusion
To study the association, independently of known risk factors, between the frailty score on admission and readmission to critical care or hospitalisation before D90, among patients discharged alive from ICU before D90.
Readmission to critical care or hospitalisation before D90, among patients discharged alive from ICU before D90.
Time frame: 90 days after inclusion
To study the association, independently of known risk factors, between the frailty score on admission and describe changes in frailty between ICU admission and D90 in patients alive at D90.
Change in frailty score defined by the CFS (continuous) between admission and D90 (in hospital or at home).
Time frame: 90 days after inclusion
To study the association, independently of known risk factors, between the frailty score on admission and describe quality of life at D90 in patients alive at D90.
Quality of life measured by the EQ5D score at D90 (in hospital or at home).
Time frame: 90 days after inclusion
Started Aug 2023 (actual). Primary completion is estimated for Sep 2027, 48 months after the start.
Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 48 months is above that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Sep 2026 → Sep 2027 and completion Nov 2026 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier de Lens